Page last updated: 2024-11-04

alpha-ketoisovalerate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Alpha-ketoisovalerate (α-KIV) is a branched-chain keto acid that is an important intermediate in the catabolism of valine, leucine, and isoleucine. It is synthesized from the corresponding branched-chain amino acids via transamination reactions catalyzed by branched-chain aminotransferase enzymes. α-KIV is then decarboxylated to isobutyryl-CoA by the enzyme branched-chain ketoacid dehydrogenase, a key step in the degradation pathway. α-KIV has been implicated in various metabolic disorders, including maple syrup urine disease (MSUD), a rare genetic disorder caused by a deficiency in the branched-chain ketoacid dehydrogenase complex. Elevated levels of α-KIV can lead to neurotoxicity and metabolic acidosis. α-KIV is also a potential therapeutic target for the treatment of metabolic diseases, such as diabetes and obesity. Researchers are studying α-KIV to understand its role in various metabolic processes, develop new therapeutic strategies, and investigate its potential contribution to the development of various diseases.'

alpha-ketoisovalerate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-methyl-2-oxobutanoate : A 2-oxo monocarboxylic acid anion that is the conjugate base of 3-methyl-2-oxobutanoic acid, arising from deprotonation of the carboxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

3-methyl-2-oxobutanoic acid : A 2-oxo monocarboxylic acid that is the 2-oxo derivative of isovaleric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID49
CHEMBL ID146554
CHEBI ID16530
SCHEMBL ID42329
MeSH IDM0041732

Synonyms (92)

Synonym
a-ketoisovaleric acid
2-ketoisovalerate
2-oxo-3-methylbutanoic acid
isopropylglyoxylic acid
2-oxo-3-methylbutyric acid
dimethylpyruvic acid
alpha-oxoisovaleric acid
alpha-oxo-beta-methylbutyricacid
2-oxoisovaleric acid
2-ketoisovaleric acid
CHEBI:16530 ,
3-methyl-2-oxo-butanoic acid
LMFA01020274
759-05-7
3-methyl-2-oxobutanoic acid
2-oxoisopentanoate
2-oxo-3-methylbutanoate
2-keto-3-methylbutyric acid
2-oxoisovalerate
alpha-oxoisovalerate
alpha-keto-isovaleric acid
3-methyl-2-oxobutanoate
2-ketovaline
alpha-keto-valine
C00141
alpha-ketovaline
3-methyl-2-oxobutyric acid
kiv ,
alpha-ketoisovaleric acid
ketovaline
DB04074
alpha-ketoisovalerate
valine, 2-oxo-
9131EA12-7229-4467-B548-60787FD0B557
butanoic acid, 3-methyl-2-oxo-
BMSE000101
CHEMBL146554 ,
AKOS006272906
3-methyl-2-oxo-butyric acid
bdbm50390989
3-methyl-2-oxobuttersaeure
34p71d50e0 ,
einecs 212-065-4
(rs)-3-methyl-2-oxobuttersaeure
unii-34p71d50e0
FT-0616073
.alpha.-keto-isovaleric acid
3-methyl-2-oxo butanoic acid
.alpha.-oxoisovaleric acid
.alpha.-oxo-.beta.-methylbutyric acid
2-oxo-isovaleric acid
.alpha.-ketoisovaleric acid
3-methyl-2-oxobutanoic acid [fhfi]
fema no. 3869, acid-
S6148
SCHEMBL42329
SY005235
mfcd00040427
DTXSID6061078
W-104383
DS-0555
CS-W006057
alpha-keto-beta-methylbutyrate
a-oxoisovalerate
2-oxo-3-methylbutyrate
isopropylglyoxylate
a-keto-b-methylbutyric acid
alpha-oxo-beta-methylbutyric acid
2-keto-3-methylbutyrate
a-keto-isovalerate
2-ketoisvaleric acid
a-oxoisovaleric acid
a-ketoisovalerate
alpha-oxo-beta-methylbutyrate
a-oxo-b-methylbutyrate
3-methyl-2-oxo-butanoate
3-methyl-2-oxobutinoic acid
3-methyl-2-oxobutinoate
alpha-keto-beta-methylbutyric acid
2-oxo-3-methyl-butyrate
a-keto-b-methylbutyrate
a-keto-isovaleric acid
dimethylpyruvate
a-oxo-b-methylbutyric acid
3-methyl-2-oxo-butyrate
HY-W006057
alpha-ketoisovaleric acid; ketovaline
Q2823217
3-methyl-2-oxobutyric aciddiscontinued
3-methyl-2-ketobutanoic acid
3-methyl-2-oxobutanoicacid
EN300-142834

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Blood levels in pharmacokinetic and absorption studies are related to the Michaelis-constants."( Enzymatic and pharmacokinetic studies on the metabolism of branched chain alpha-keto acids in the rat.
Bässler, KH; Pietrek, A, 1983
)
0.27

Dosage Studied

ExcerptRelevanceReference
" We conclude that at least half of KIC and KIV given orally in this dosage is oxidized in splanchnic organs during first pass but that, nevertheless, these keto acids given orally serve as significant sources of the intracellular amino acids used for protein synthesis in most organs, particularly brain and heart."( Utilization for protein synthesis of leucine and valine compared with their keto analogues.
Shiota, T; Swain, LM; Walser, M, 1990
)
0.28
" KIV elicited clonic convulsions in a dose-response manner, whereas KIC and KMV did not induce seizure-like behavior."( Pharmacological evidence that alpha-ketoisovaleric acid induces convulsions through GABAergic and glutamatergic mechanisms in rats.
Coitinho, AS; de Bastiani, J; de Mello, CF; Fighera, MR; Lima, TT; Wajner, M, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
branched-chain keto acidAn oxo carboxylic acid in which the parent hydrocarbon chain has one or more alkyl substituents. Derivatives formed from the first step in the metabolism of branched-chain amino acids and can provide important information on animal health and disease.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (31)

PathwayProteinsCompounds
Valine, Leucine, and Isoleucine Degradation2852
beta-Ketothiolase Deficiency2852
2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency2852
Propionic Acidemia2852
3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency2852
Maple Syrup Urine Disease2852
3-Methylcrotonyl-CoA Carboxylase Deficiency Type I2852
3-Methylglutaconic Aciduria Type I2852
3-Methylglutaconic Aciduria Type III2852
Methylmalonate Semialdehyde Dehydrogenase Deficiency2852
Methylmalonic Aciduria2852
Isovaleric Aciduria2852
3-Methylglutaconic Aciduria Type IV2852
3-Hydroxyisobutyric Acid Dehydrogenase Deficiency2852
3-Hydroxyisobutyric Aciduria2852
Isobutyryl-CoA Dehydrogenase Deficiency2852
Isovaleric Acidemia2852
L-Alanine Metabolism1016
Valine Degradation710
2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency2952
Valine,Leucine and Isoleucine degradation ( Valine,Leucine and Isoleucine degradation )2936
2-Oxo-glutaric acid + L-Valine = L-Glutamic acid + 3-Methyl-2-oxo-butanoic acid ( Valine,Leucine and Isoleucine degradation )24
Glucosinolate biosynthesis from branched-chain amino acid012
branched-chain u03B1-keto acid dehydrogenase complexes06
pantothenate and coenzyme A biosynthesis022
Valine, leucine and isoleucine degradation034
Biochemical pathways: part I0466
Leucine biosynthesis015
Valine biosynthesis112
Valine degradation817
Pantothenate biosynthesis I117
Pantothenate biosynthesis II117

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Monocarboxylate transporter 1Rattus norvegicus (Norway rat)Km1,250.00002.28002.66503.0500AID681605
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
lactate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
pyruvate catabolic processMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transportMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
RNA bindingMonocarboxylate transporter 4Homo sapiens (human)
protein bindingMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
lactate:proton symporter activityMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
apical plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
lateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
nuclear membraneMonocarboxylate transporter 4Homo sapiens (human)
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID681123TP_TRANSPORTER: inhibition of lactate uptake in Xenopus laevis oocytes1999The Biochemical journal, Aug-01, Volume: 341 ( Pt 3)Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.
AID681605TP_TRANSPORTER: change in intracellular pH(pHi)value in Xenopus laevis oocytes1998The Biochemical journal, Jul-01, Volume: 333 ( Pt 1)Characterization of the monocarboxylate transporter 1 expressed in Xenopus laevis oocytes by changes in cytosolic pH.
AID681140TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of physiology, Dec-01, Volume: 529 Pt 2Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (178)

TimeframeStudies, This Drug (%)All Drugs %
pre-199076 (42.70)18.7374
1990's38 (21.35)18.2507
2000's30 (16.85)29.6817
2010's29 (16.29)24.3611
2020's5 (2.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.55 (24.57)
Research Supply Index5.22 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.10%)5.53%
Reviews6 (3.30%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other174 (95.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]